References
- Angell SY, De Cock KM, Frieden TR. A public health approach to global management of hypertension. Lancet. 2015;385(9970):825–27. doi:https://doi.org/10.1016/S0140-6736(14)62256-X.
- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23. doi:https://doi.org/10.1016/S0140-6736(05)17741-1.
- Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, et al. Hypertension. Nat Rev Dis Primers. 2018;4(1):18014. doi:https://doi.org/10.1038/nrdp.2018.14.
- Wadei HM, Textor SC. The role of the kidney in regulating arterial blood pressure. Nat Rev Nephrol. 2012;8(10):602–09. doi:https://doi.org/10.1038/nrneph.2012.191.
- Calvillo L, Gironacci MM, Crotti L, Meroni PL, Parati G. Neuroimmune crosstalk in the pathophysiology of hypertension. Nat Rev Cardiol. 2019;16(8):476–90. doi:https://doi.org/10.1038/s41569-019-0178-1.
- Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol. 2019;19(8):517–32. doi:https://doi.org/10.1038/s41577-019-0160-5.
- Chen K, Fu C, Chen C, Jose PA, Zeng C. Role of GRK4 in the regulation of arterial AT1 receptor in hypertension. Hypertens. 2014;63(2):289–96. doi:https://doi.org/10.1161/HYPERTENSIONAHA.113.01766.
- Yang J, Villar VA, Jones JE, Jose PA, Zeng C. G protein-coupled receptor kinase 4: role in hypertension. Hypertens. 2015;65(6):1148–55. doi:https://doi.org/10.1161/HYPERTENSIONAHA.115.05189.
- Lu X, Ye Z, Zheng S, Ren H, Zeng J, Wang X, Jose PA, Chen K, Zeng C. Long-term exposure of fine particulate matter causes hypertension by impaired renal D1 receptor-mediated sodium excretion via upregulation of G-protein-coupled receptor kinase type 4 expression in sprague-dawley rats. J Am Heart Assoc. 2018;7(1):e007185. doi:https://doi.org/10.1161/JAHA.117.007185.
- Wang Z, Zeng C, Villar VA, Chen SY, Konkalmatt P, Wang X, Asico LD, Jones JE, Yang Y, Sanada H, et al. Human GRK4γ142V variant promotes angiotensin II type I receptor-mediated hypertension via renal histone deacetylase type 1 inhibition. Hypertens. 2016;67(2):325–34. doi:https://doi.org/10.1161/HYPERTENSIONAHA.115.05962.
- Wang Y, Li B, Zhao W, Liu P, Zhao Q, Chen S, Li H, Gu D. Association study of G protein-coupled receptor kinase 4 gene variants with essential hypertension in northern Han Chinese. Ann Hum Genet. 2006;70(pt6):778–83. doi:https://doi.org/10.1111/j.1469-1809.2006.00278.x.
- Iniesta R, Campbell D, Venturini C, Faconti L, Singh S, Irvin MR, Cooper-dehoff RM, Johnson JA, Turner ST, Arnett DK, et al. Gene variants at Loci related to blood pressure account for variation in response to antihypertensive drugs between black and white individuals. Hypertens. 2019;74(3):614–22. doi:https://doi.org/10.1161/HYPERTENSIONAHA.118.12177.
- Weeke P, Roden DM. Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med. 2014;65(1):81–94. doi:https://doi.org/10.1146/annurev-med-101712-122545.
- Pierdomenico SD, Pierdomenico AM, Coccina F, Lapenna D, Porreca E. Prognostic value of nondipping and morning surge in elderly treated hypertensive patients with controlled ambulatory blood pressure. Am J Hypertens. 2017;30(2):159–65. doi:https://doi.org/10.1093/ajh/hpw145.
- Asayama K, Satoh M, Kikuya M. Diurnal blood pressure changes. Hypertens Res. 2018;41(9):669–78. doi:https://doi.org/10.1038/s41440-018-0054-0.
- Crnko S, Du Pré BC, Sluijter JPG, Van Laake LW. Circadian rhythms and the molecular clock in cardiovascular biology and disease. Nat Rev Cardiol. 2019;16(7):437–47. doi:https://doi.org/10.1038/s41569-019-0167-4.
- O’Brien E, Sheridan J, O’Malley K. Dippers and non-dippers. Lancet. 1988;2(8607):397. doi:https://doi.org/10.1016/s0140-6736(88)92867-x.
- Higashi Y, Nakagawa K, Kimura M, Noma K, Hara K, Sasaki S, Goto C, Oshima T, Chayama K, Yoshizumi M. Circadian variation of blood pressure and endothelial function in patients with essential hypertension: acomparison of dippers and non-dippers. J Am Coll Cardiol. 2002;40(11):2039–43. doi:https://doi.org/10.1016/s0735-1097(02)02535-4.
- Peixoto AJ, White WB. Circadian blood pressure: clinical implications based on the pathophysiology of its variability. Kidney Int. 2007;71(9):855–660. doi:https://doi.org/10.1038/sj.ki.5002130.
- Lemmer B. The importance of circadian rhythms on drug response in hypertension and coronary heart disease from mice and man. Pharmacol Ther. 2006;111(3):629–51. doi:https://doi.org/10.1016/j.pharmthera.2005.11.008.
- Yang K, Wang Y, Ding Y, Cui H, Zhou D, Chen L, Ma Z, Wang W, Zhang W, Luan J. Valsartan chronotherapy reverts the non-dipper pattern and improves blood pressure control through mediation of circadian rhythms of the renin-angiotensin system in spontaneous hypertension rats. Chronobiol Int. 2019;36(8):1058–71. doi:https://doi.org/10.1080/07420528.2019.1610419.
- Rayner B, Ramesar R. The importance of G protein-coupled receptor kinase 4 (GRK4) in pathogenesis of salt sensitivity, salt sensitive hypertension and response to antihypertensive treatment. Int J Mol Sci. 2015;16(3):5741–49. doi:https://doi.org/10.3390/ijms.16035741.
- Chugh G 1, Pokkunuri I, Asghar M. Renal dopamine and angiotensin II receptor signaling in age-related hypertension. Am J Physiol Renal Physiol. 2013;304(1):F1–7. doi:https://doi.org/10.1152/ajprenal.00441.2012.
- Harris RC. Abnormalities in renal dopamine signaling and hypertension: the role of GRK4. Curr Opin Nephrol Hypertens. 2012;21(1):61–65. doi:https://doi.org/10.1097/MNH.0b01.3e32834de2cb.
- Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA. 2014;311(21):2216–24. doi:https://doi.org/10.1001/jama.2014.5180.
- Cooper-dehoff RM, Johnson JA. Hypertension pharmacogenomics: in search of personalized treatment approaches. Nat Rev Nephrol. 2016;12(2):110–22. doi:https://doi.org/10.1038/nrneph.2015.176.
- Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circ. 2005;111(25):3374–83. doi:https://doi.org/10.1161/CIRCULATIONAHA.104.504639.
- Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST, Chapman AB. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008;21(1):61–66. doi:https://doi.org/10.1038/ajh.2007.24.
- Smolensky MH, Hermida RC, Portaluppi F. Circadian mechanisms of 24-hour blood pressure regulation and patterning. Sleep Med Rev. 2017;33:4–16. doi:https://doi.org/10.1016/j.smrv.2016.02.003.
- Stergiou GS, Vemmos KN, Pliarchopoulou KM, Synetos AG, Roussias LG, Mountokalakis TD. Parallel morning and evening surge in stroke onset, blood pressure, and physical activity. Stroke. 2002;33(6):1480–86. doi:https://doi.org/10.1161/01.str.0000016971.48972.14.
- Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49(11):1157–63. doi:https://doi.org/10.1016/j.jacc.2006.11.032.
- Zakopoulos NA, Tsivgoulis G, Barlas G, Papamichael C, Spengos K, Manios E, Ikonomidis I, Kotsis V, Spiliopoulou I, Vemmos K, et al. Time rate of blood pressure variation is associated with increased common carotid artery intima-media thickness. Hypertens. 2005;45(4):505–12. doi:https://doi.org/10.1161/01.HYP.0000158306.87582.43.